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TAKE HOME MESSAGE 
One third of adults with neuromuscular disease received specialist respiratory care. Emergent healthcare use was 
substantial, emphasizing an urgent need to improve community and social supports. 
 
TWEET 
Emergent healthcare use of neuromuscular disease is substantial; urgent need to improve community and social 
supports.  
 
 
  
ABSTRACT 
To quantify health service utilisation including monitoring and treatment of respiratory complications for adults with 
neuromuscular disease (NMD) identifying practice variation and adherence to guideline recommendations at a 
population level.  
 
Population-based longitudinal cohort study (2003 to 2015) of adults with NMD using hospital diagnostic and health 
insurance billing codes within administrative health databases. 
 
We identified 185,586 adults with NMD. Mean age 52 years, 59% female. 41,173 (22%) went to an emergency 
department (ED) for respiratory complications on average 1.6 times every 3 years; 14,947 (8%) individuals were 
admitted to hospital 1.4 times every 3 years. Outpatient respiratory specialist visits occurred for 64,084 (35%) with 4 
visits every 3 years though substantial variation in visit frequency was found. 157,285 (85%) went to the ED (all 
cause) almost 4 times every 3 years, 100,052 (54%) were admitted to hospital. Individuals with ALS had more ED 
visits compared to other types of NMD (P <0.0001).  
 
One third of adults with NMD received respiratory specialist care at a frequency recommended by professional 
guidelines though substantial variation exists. Emergent healthcare utilisation was substantial, emphasizing the burden 
of NMD on the healthcare system and urgent need to improve community and social supports, particularly for ALS 
patients. 
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INTRODUCTION 
Individuals with neuromuscular disorders (NMD) experience progressive respiratory muscle weakness and are at high 
risk of respiratory insufficiency [1] due to hypoventilation during sleep [2, 3], recurrent atelectasis, and pneumonia [4] 
resulting from decreased cough effectiveness [5]. Neuromuscular disorders include a heterogeneous spectrum of 
diseases that affect muscle and nerve function, many of which are genetic, represent extremely complex 
pathophysiology, have varying degrees of severity, and require high levels of care [6]. Although some NMD are rare, 
when considered as a group these disorders are relatively common with an estimated prevalence of about 1 in 3,000 
[7].  
 
For most individuals with NMD, increased healthcare requirements related to respiratory problems and the need for 
assistive respiratory technology indicate progression of disease, and increased morbidity and mortality [8]. Acute 
respiratory failure due to respiratory infection is a frequent reason for unplanned hospital admission, although there 
are limited empirical data on patterns of healthcare utilisation in this patient population. Chronic respiratory failure is 
the most common cause of death [7]. The primary aim of respiratory management is prevention and timely 
management of respiratory related complications, as well as symptom control [9]. Proactive monitoring of pulmonary 
function [8], appropriate use of respiratory interventions such as lung volume recruitment [5], manual or mechanical 
cough augmentation [10], and non-invasive ventilation [11] may either prevent or manage progressive respiratory 
insufficiency, thus reducing unplanned hospital admissions and improving health related quality of life and longevity.  
 
Several consensus documents inform evidence and expert derived best practices which, when adopted, may reduce 
clinical practice variation and improve the appropriateness of respiratory assessment and management of individuals 
with NMD [7, 9, 12-19]. Recommendations for management of respiratory health in this population include: access to 
respiratory and/or sleep specialists early in the disease course; measurement at baseline and over time of lung 
function, oximetry, and as indicated CO2, and outpatient clinic visits to assess respiratory symptom progression every 
3, 6 or 12 months dependent on disease progression and initiation of ventilation. Despite these consensus statements, 
surveys of service providers or care recipients suggest variation in respiratory management practices [20, 21] and 
respiratory complications remain a primary cause of morbidity and mortality [8].  
 To address gaps in knowledge related to adherence to guideline recommendations at a population level, we conducted 
a North American population based cohort study using administrative databases to quantify health service utilisation, 
with a particular focus on services used for assessing, monitoring, and treating respiratory complications for adults 
with NMD. We hypothesized that frequency of monitoring and respiratory specialist care would be variable but 
should increase with initiation of mechanical ventilation. Secondary objectives were to explore: (1) all cause publicly 
funded health service utilisation; (2) variables associated with emergency department (ED) presentation or hospital 
admission; and (3) changes in healthcare utilisation before and after initiation of home mechanical ventilation (HMV).  
 
METHODS 
We conducted a retrospective longitudinal population-based cohort study from April 1st 2003 to March 31st 2015 
using health administrative databases for the province of Ontario, Canada held at the Institute for Clinical Evaluative 
Sciences (ICES) using unique encoded identifiers to link databases. These databases contain anonymized data for all 
Ontario residents. Ontario, is the most populous Canadian province with a population of approximately 13 million 
[22]. Costs of all medically necessary care are covered for all residents by universal public health insurance funded 
through general taxation. Respiratory equipment such as ventilators, continuous positive airway pressure (CPAP) and 
bilevel devices is publicly funded through the Assistive Devices Program (ADP). 
 
Data Sources and Population  
We linked databases at the level of the individual using unique encoded identifiers to identify: (1) hospitalizations 
including demographic, diagnostic and procedural data, and in-hospital death in the Discharge Abstract Database; (2) 
ED presentations in the National Ambulatory Care Reporting System; (3) physician billings including procedures in 
the Ontario Health Insurance Plan (OHIP) database [23]; (4) approvals of assistive devices including ventilators, 
suction equipment, and supplies in the ADP database; (5) inpatient rehabilitation using the National Rehabilitation 
Reporting System; (6) facility based continuing (residential) care services in the Continuing Care Reporting System; 
(7) home care services using the Home Care Database; and death outside of hospital using the (8) Registered Persons 
Database. To describe immigration status we used the Immigration, Refugees and Citizenship Canada’s Permanent 
Resident Database. This database contains individual-level demographic data on all immigrants who became 
permanent residents between 1985 and 2012. Following well-established methods, both neighbourhood income and 
urban/rural place of residence were ascertained using postal codes  and linking to Statistics Canada census data [24]. 
To identify respiratory specialist care, we used the ICES Physician Database (IPDB) that contains information about 
all physicians in Ontario.   
 
We created a cohort of adults aged 18 to 105 years using hospital diagnostic codes (International Classification of 
Disease (ICD-9, ICD-10) or physician billing codes a priori considered specific to NMD within health administration 
databases from April 1st 2003 to March 31st 2008. Within this 5 year period we sought the first instance of these codes 
considered the ‘most responsible’ or secondary contributing diagnoses in the hospitalization database [25] indicating 
hospital admission with a NMD diagnosis. For individuals with a NMD diagnostic code found using the ambulatory 
care database, we included only those whose NMD diagnosis was confirmed by looking backwards and forwards in 
time in the hospitalization database (1998-2014) for a NMD-related hospital admission. For those without hospital 
admission we reviewed the physician-billing database for NMD-related billing in these years. For individuals 
identified using the OHIP billing code 349 (NMD diagnosis non-specific), we again looked backwards and forwards 
in the hospitalization (1998-2014) and ambulatory care (2000-2014) databases to establish NMD diagnosis and sought 
OHIP billings from a neurologist or for an electromyogram enabling more accurate classification. 
 
We grouped diagnostic codes for NMD (ICD and OHIP) into 12 categories: amyotrophic lateral sclerosis/motor 
neurone disease (ALS/MND); cerebral palsy [26]; Guillain-Barre [27]; metabolic disorders; multiple sclerosis [28]; 
muscular dystrophy; myasthenia gravis [29]; neuromuscular disorders (non-specific); neuropathy; post-polio 
syndrome; spina bifida; and spinal muscular atrophy. For modelling purposes we further grouped these NMD 
categories as rapidly progressive (ALS/MND), slowly or non-progressive (Guillain-Barre syndrome; myasthenia 
gravis; neuropathy; post-polio syndrome, spinal muscular atrophy), variably progressive (metabolic disorders; 
muscular dystrophy; neuromuscular disorders (non-specific)), and other (cerebral palsy; multiple sclerosis; spina 
bifida)  [30]. We used previously validated case definitions for asthma [31], COPD [32], congestive heart failure [33] 
and ICD-10 codes for cardiomyopathy and arrhythmias. We determined Collapsed Aggregated Diagnosis Groups 
(CADG) [34] and calculated the Charlson co-morbidity score considering all hospitalizations within 2 years prior to 
identification of NMD.   
 
Outcomes 
To evaluate healthcare utilisation we followed our 2003-2008 cohort from identification of NMD to March 31st 2015 
(minimum of seven years). Our primary outcome was health service utilisation for assessment, monitoring, and 
management of respiratory complications including respiratory related ED presentations and hospital admissions; 
consultations with a respiratory specialist (in-hospital and ambulatory/outpatient clinic); pulmonary function testing 
(PFT); polysomnography (PSG); access to community respiratory therapists; and use of respiratory therapies in the 
community including oxygen, mechanical ventilation; and airway clearance devices.  
 
Additional healthcare utilisation outcomes: all cause ED visits, hospital and ICU admissions; duration of ED, hospital 
and ICU stay; outpatient clinic visits and in-patient services by specialists other than respiratory; in-patient 
rehabilitation; homecare services; and long-term care residence. We examined associations of the a priori identified 
demographic and clinical variables with frequency of ED presentation and  hospital admission: NMD category [30]; 
age; sex; neighbourhood income quintile; rural residence; immigration status; ventilation status; use of other medical 
technologies, comorbidities i.e., COPD, asthma, CHF, myopathy, arrhythmias; and CADGs [34]. We also compared 
healthcare utilisation in the one and three years before and after initiation of mechanical ventilation in a subset of the 
cohort with three years of follow-up data after initiation of mechanical ventilation.  
 
Ethical considerations  
We conducted our study according to a pre-specified protocol approved by the Research Ethics Board at Sunnybrook 
Health Sciences Centre, Toronto, Ontario and according to privacy regulations of ICES. 
 
Statistical analyses 
We used descriptive statistics to characterize our cohort. We report counts, overall proportion, and mean (standard 
deviation (SD)) frequency every three years per individual for rates of healthcare utilisation, as well as mean (SD) and 
median (interquartile range (IQR)) duration of healthcare utilisation (i.e., hospital admission). We created generalized 
linear regression models with negative binomial distribution to examine variables associated with frequency of ED 
presentation or hospital admissions while controlling for the variables described above and using exposure time as an 
offset variable. We compared healthcare utilization before and after initiation of HMV using t tests. We conducted 
analyses in SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
In the 5-year cohort creation-period, we identified 185,586 adults with NMD. Of these, we identified 2249 (1.2%) 
through ED presentation, 10,656 (5.7%) through hospitalization, and 172,681 (93.0%) through physician billing only. 
At baseline, mean age was 52 years, 59% were female, and 89% lived in an urban location. Asthma (15%) and COPD 
(12%) were fairly common respiratory comorbidities (Table 1; Supplementary Table 1 for the 12 disease groupings). 
 
Table 1 Cohort characteristics (2003 to 2008) 
 
Total 
Rapidly 
progressive 
Slowly/non-
progressive 
Variably 
progressive 
Other 
Total N 185,586 864 32,054 104,865 47,803 
Age (years) 
Mean (SD) 52 (16.4) 71.2 (11.9) 53.51 (16.8) 54.39 (16.1) 45.69 (15.2) 
18 - 39 44,044 (23.7) 15 (1.7) 7,023 (21.9) 19,640 (18.7) 17,366 (36.6) 
40 - 64  96,903 (52.2) 185 (21.4) 16,330 (50.9) 55,523 (52.9) 24,865 (52.0) 
65 + 44,639 (24.1) 664 (76.9) 8,701 (27.1) 29,702 (28.3) 5,572 (11.7) 
Sex 
Female  109,919 (59.2) 354 (41.0) 17,796 (55.5) 59,410 (56.7) 32,359 (67.7) 
Male  75,667 (40.8) 510 (59.0) 14,258 (44.5) 45,455 (43.4) 15,444 (32.3) 
Neighbourhood income quintilea 
1 (poorest/lowest) 35,603 (19.2) 194 (22.6) 6,449 (20.2) 19,547 (18.7) 9,413 (19.8) 
2  36,884 (19.9) 183 (21.3) 6,794 (21.2) 20,546 (19.7) 9,361 (19.6) 
3  36,488 (19.7) 175 (20.4) 6,695 (20.9) 20,324 (19.4) 9,294 (19.5) 
4  37,672 (20.3) 153 (17.8) 6,103 (19.1) 21,746 (20.8) 9,670 (20.3) 
5 (richest/highest) 38,406 (20.7) 155 (18.0) 5,939 (18.6) 22,394 (21.4) 9,918 (20.8) 
Rural residenceb 
No  164,879 (88.8) 739 (85.5) 28,872 (90.1) 93,349 (89.1) 41,919 (87.8) 
Yes   20,604 (11.1) 125 (14.5) 3,172 (9.9) 11,459 (10.9) 5,848 (12.2) 
Immigration statusc 
Citizen  169,504 (91.3) 812 (94.0) 28,072 (87.6) 95,935 (91.5) 44,685 (93.5) 
Immigrantd  12,917 (7.0) 44 (5.1) 3,230 (10.1) 7,107 (6.8) 2,536 (5.3) 
Refugee  3,154 (1.7) 8 (0.9) 752 (2.4) 1,815 (1.7) 579 (1.2) 
Comorbidity      
COPD 22,162 (11.9) 264 (30.6) 4,070 (12.7) 14,285 (13.6) 3,543 (7.4) 
Asthma   28,720 (15.5) 133 (15.4) 4,769 (14.9) 17,414 (16.6) 6,404 (13.4) 
CHF 8,310 (4.5) 134 (15.5) 1,570 (4.9) 5,606 (5.4) 1,000 (2.1) 
Charlson Comorbidity Indexe 
0  28,360 (15.3) 369 (46.4) 5,034 (57.6) 14,822 (53.3) 8,135 (70.5) 
1 (1 to 3)  16,871 (9.1) 361 (45.4) 3,050 (34.9) 10,502 (37.8) 2,958 (25.6) 
2 (≥4)  3,642 (2.0) 66 (8.3) 650 (7.4) 2,475 (8.9) 451 (3.9) 
Note: some percentages may not sum to 100 due to rounding.  
Rapidly progressive: Amyotrophic Lateral Sclerosis/motor neurone disease  
Slowly/non progressive disease comprises: Guillain-Barre syndrome; myasthenia gravis; neuropathy; post-polio 
syndrome, spinal muscular atrophy 
Variably progressive comprises: metabolic disorders; muscular dystrophy; neuromuscular disorders (non-specific 
physician billing diagnostic codes) 
Other: cerebral palsy; multiple sclerosis; spina bifida. 
a Unable to establish for 533 (0.3%) individuals. 
b Unable to establish for 103 (0.06%) individuals.  
c Unable to establish for 11 (0.0006%)individuals. 
d Immigrant is defined as resident within Ontario as holding either Canadian permanent residency status or a 
work, student, or other form of visa. 
e Charlson comorbidity index calculated for those admitted to hospital considering all hospitalizations within 2 
years prior to the index event (48,873 patients). 
 
Health service utilisation for respiratory complications 
From fiscal years 2003-2014, subsequent to identification of NMD diagnosis, 41,173 (22%) individuals went to the 
ED for respiratory reasons for a total of 85,066 visits with a median (IQR) length of stay 5.2 (2.5-12.4) hours. 14,947 
(8%) individuals were admitted to hospital (24,929 admissions) for respiratory reasons with a median (IQR) length of 
stay 7 (3-17) days. On average, individuals with NMD went to the ED 1.6 times every 3 years and were admitted to 
hospital 1.4 times every 3 years for respiratory causes. Outpatient clinic visits to a respiratory specialist occurred for 
64,084 (35%) individuals with an average of 4 visits every 3 years, though there was substantial variation in the 
number of visits per individual and those with ALS/MND or muscular dystrophy had an average of 17 and 7.5 visits 
per individual every 3 years respectively. In-hospital pulmonologist consultation occurred for 17,489 (9%) with the 
mean (SD) number of consultations falling from 6.6 (13.7) in 2003-2005 to 4.5 (16.1) in 2012-2014. Pulmonary 
function testing was conducted in 60,388 (33%) individuals with a mean (SD) number of tests every 3 years for the 
entire group receiving testing ranging from 1.9 (2.0) in years 2003-2005 to 2.2 (3.4) in years 2012-2014 and similar 
frequencies for individuals with muscular dystrophy and ALS/MND (Supplementary Table 2). Polysomnography was 
conducted in 26,070 (14%) individuals with testing frequency every 3 years similar over time (Table 2; See 
Supplementary Table 2 for all health service utilisation for individuals with muscular dystrophy and ALS/MND). A 
publicly funded continuous positive airway pressure (CPAP) device was supplied to 7,737 (4.2%) individuals, long-
term oxygen therapy (LTOT) to 4,750 (2.6%), and 1,446 (0.8%) were supplied a publicly funded  ventilator (invasive 
(176) or non-invasive bilevel device (1,270)) for HMV. Over 50% of individuals requiring LTOT had COPD and/or 
CHF as a comorbidity (Table 3). Only 71 (0.04%) individuals received services from publicly funded respiratory 
therapy providers in the community, reflective, not of a lack of need but of the lack of public funding in Ontario for 
community respiratory therapy. 
 
Other health service utilisation 
From 2003-2014, subsequent to identification of NMD, 157,285 (85%) individuals went to the ED for 1,202,800 
visits (all cause) with a median (IQR) length of stay 19.1 [7.6-47] hours. 100,052 (54%) (301,064 admissions) were 
admitted to hospital (median (IQR) length of stay 9 (3-28) days). On average, individuals with NMD visited the ED 
(all-cause) almost 4 times every 3 years and were admitted to hospital (all-cause) twice every 3 years. One or more 
ICU admissions were required for 29,453 (16%) individuals with a total of 53,200 ICU admissions and a median 
(IQR) length of stay of 3.6 (1.6-8.4) days. Outpatient clinic visits to physician specialists other than respiratory 
specialists occurred for 184,950 (99.6%) individuals with average visit frequency every 3 years increasing over time 
from 23.8 to 30.1; 128,775 (69%) had in-hospital specialist (non-respiratory) consultation (Table 2). The most 
commonly consulted non-respiratory specialists in the outpatient setting were surgeons (46,760, 25%), family 
medicine (28,780, 16%), and internal medicine (16,852, 9%); only 18,388 (10%) were seen by a neurologist. 
Admission to a rehabilitation facility occurred for 13,671 (7.4%) individuals with a median (IQR) length of stay of 28 
(14-51) days. Admission to a long-term care facility occurred for 9,042 (4.9%) individuals. Of the cohort, 70,033 
(38%) NMD individuals received home care services for a median (IQR) of 32 (9-195) hours overall in the year 
services were approved. The most common services were from registered nurses (23,831, 13%), case managers 
(11,914, 6%), and combined personal support/homemaker services (10,178, 5%). In the follow-up period 34,336 
(18.5%) died. 
 Table 2 Health service utilisation after NMD diagnosis 
Health service 
N = 185,586 adults 
n (%) patients 
 
Overall visits per 
individuala 
Number of visits per  three years per individualb 
2003- 
2005 
2006- 
2008 
2009- 
2011 
2012- 
2014 
Respiratory related ED visits   41,173 (22.2) 2.1 (2.6); 1 (1,2) 1.5 (1.2) 1.5 (1.3) 1.6 (1.4) 1.6 (1.6) 
Respiratory related hospital admission  14,947 (8.0) 1.7 (1.6); 1 (1,2) 1.4 (1.0) 1.4 (1.0) 1.4 (1.0) 1.4 (1.1) 
Pulmonology outpatient clinic  64,084 (34.5) 5.9 (22.4); 2 (1,5) 3.8 (11.8) 3.9 (13.1) 4.1 (11.9) 4.0 (11.6) 
Hospital pulmonology consult 17,489 (9.4) 6.6 (28.4); 3 (1,6) 6.6 (13.7) 6.4 (17.9) 5.0 (19.6) 4.5 (16.1) 
Pulmonary function tests 60,388 (32.5) 3.2 (5.4; 2 (1,3) 1.9 (2) 2.1 (2.8) 2.2 (3.2) 2.2 (3.4) 
Sleep studies 26,070 (14.0) 1.8 (1.2; 1 1,2) 1.5 (0.7) 1.5 (0.8) 1.4 (0.6) 1.4 (0.6) 
Outpatient clinic (non-pulmonology) 184,950 (99.6) 94.4 (84.5); 74 (42,121) 23.8 (28.5) 27.8 (28.9) 32.2 (30.2) 30.1 (29.0) 
Hospital consult (non-pulmonology) 128,775 (69.4) 20.2 (36.2); 6 (2,22) 12.2 (21.5) 11.9 (22.2) 11 (21.3) 11.1 (21.4) 
All cause ED visits  157,285 (84.8) 7.7 (13.4); 4 (2,9) 3.1 (5.2) 3.4 (5.6) 3.7 (6.1) 3.7 (5.5) 
All cause hospital admission  100,052 (53.9) 3.0 (3.3); 2 (1,4) 1.8 (1.6) 1.9 (1.6) 1.9 (1.7) 2.0 (1.8) 
ICU admission 29,453 (15.9) 1.8 (1.6); 1 (1,2) 1.5 (1.1) 1.5 (1.0) 1.5 (1.1) 1.5 (1.1) 
a Values are mean (standard deviation); median (interquartile range) during cohort follow up. 
b Calculated for individuals in the cohort requiring these services within each three-year time period. 
ED: Emergency department; ICU: intensive care unit.
Table 3 Diagnosis of patients receiving home respiratory support 
  
CPAP 
n =7737 
 LTOT 
n =4750 
HMV 
n = 1446 
Neuromuscular disorders (non-
specific) 4713 (60.9) 2500 (52.6) 769 (52.9) 
Myasthenia gravis 1255 (16.2) 722 (15.2) 149 (10.2) 
Multiple sclerosis 1051 (13.6) 652 (13.7) 124 (8.5) 
Muscular dystrophy 334 (4.3) 332 (7) 245 (16.9) 
Cerebral palsy 180 (2.3) 170 (3.6) 34 (2.3) 
Spina bifida 95 (1.2) 65 (1.4) 36 (2.5) 
Neuropathy 46 (0.6) 84 (1.8) 20 (1.4) 
Guillain-Barre syndrome  35 (0.5) 44 (0.9) 16 (1.1) 
Metabolic disorders 28 (0.4) 99 (2.1) < 6(NA) 
ALS/MND < 6 80 (1.7) 53 (3.6) 
SMA - < 6 < 6 
Post-polio syndrome - - - 
Comorbidities    
COPD 964 (12.5) 1792 (37.7) 283 (19.5) 
CHF 248 (3.2) 865 (18.2) 92 (6.3) 
CPAP: continuous positive airway pressure; LTOT: long-term oxygen therapy; HMV: home mechanical ventilation; ALS: 
amyotrophic lateral sclerosis; MND: motor neurone disease; SMA: spinal muscular atrophy; COPD: chronic obstructive 
pulmonary disease; CHF: chronic heart failure 
 
Variables Associated with ED Presentation or Hospital Admission 
Individuals with ALS/MND had more ED visits compared to other types of NMD. Those with variably progressive 
disease had more hospital admissions (P <0.0001). Individuals with spina bifida, cerebral palsy, or multiple sclerosis 
had the fewest hospital admissions (P <0.0001). Those in the oldest age category had more ED visits and the most 
hospital admissions (all P values <.0001). Males, individuals in the poorest income quintile, Canadian citizens (as 
compared to immigrants or refugees), those living in rural locations, those requiring assistive ventilation or other 
medical technology had more ED visits and hospital admissions (all P values <.0001). Individuals with comorbidity 
had more ED visits and hospital admissions, with those with CHF having the most ED visits and those with 
cardiomyopathy the most hospital admissions (Table 4). 
 
Table 4 Variables associated with the number of ED visits and hospital admissions after NMD diagnosis 
 ED visits Hospital admissions 
Variables IRRb 95% CI P value IRRb 95% CI P value 
Neuromuscular disease (reference = non or slowly progressive)   
Rapidly progressive 4.36 3.89 - 4.88 <.0001 1.27 0.98 - 1.65 0.0677 
Variably progressive 1.12 1.1 - 1.13 <.0001 1.22 1.17 - 1.27 <.0001 
Other (spina bifida, cerebral 
palsy, multiple sclerosis) 
 
1.18 
 
1.16 - 1.2 <.0001 
 
0.84 
 
0.8 - 0.88 <.0001 
Age (reference = age 18-39 years)   
40-64 years 0.81 0.8 - 0.83 <.0001 1.06 1.02 - 1.1 0.0044 
65 years and older 1.03 1.01 - 1.05 0.0021 2.17 2.08 - 2.27 <.0001 
Female 0.89 0.87 - 0.9 <.0001 0.89 0.86 - 0.91 <.0001 
Neighbourhood income quintile (reference = 1 poorest/lowest)   
Income quintile 2 0.83 0.82 - 0.85 <.0001 0.86 0.82 - 0.9 <.0001 
Income quintile 3 0.76 0.74 - 0.77 <.0001 0.83 0.79 - 0.87 <.0001 
Income quintile 4 0.7 0.68 - 0.71 <.0001 0.79 0.76 - 0.83 <.0001 
Income quintile 5 0.64 0.63 - 0.65 <.0001 0.72 0.69 - 0.75 <.0001 
Rural residence 1.92 1.89 - 1.96 <.0001 1.19 1.13 - 1.24 <.0001 
Immigration status (reference = citizen)   
Immigrant 0.63 0.61 - 0.64 <.0001 0.83 0.78 - 0.88 <.0001 
Refugee 0.76 0.72 - 0.8 <.0001 0.77 0.68 - 0.86 <.0001 
Ventilation status (reference  = none)   
Invasive ventilation 2.34 1.82 - 3.01 <.0001 2.83 1.65 - 4.87 0.0002 
Non-invasive ventilation 1.69 1.51 - 1.88 <.0001 1.47 1.14 - 1.91 0.003 
Use of other medical technologya 1.82 1.68 - 1.98 <.0001 3.51 2.98 - 4.12 <.0001 
Comorbidities       
COPD 1.41 1.38 - 1.44 <.0001 1.52 1.45 - 1.58 <.0001 
CHF 1.71 1.66 - 1.77 <.0001 1.76 1.65 - 1.88 <.0001 
Asthma 1.3 1.28 - 1.33 <.0001 1.24 1.19 - 1.29 <.0001 
Cardiomyopathy 1.33 1.14 - 1.56 0.0004 2.18 1.59 - 3 <.0001 
Arrhythmias 1.45 1.38 - 1.53 <.0001 1.87 1.69 - 2.08 <.0001 
Collapsed Aggregated Diagnosis Group (reference  = few 1-7)   
Many (8-16) 1.74 1.72 - 1.76 <.0001 1.46 1.42 - 1.51 <.0001 
None 0.84 0.79 - 0.89 <.0001 1.1 0.95 - 1.26 0.2092 
a individuals requiring any of the following: gastrostomy, ileostomy, colostomy, cystostomy, or pacemaker and 
functional implants. 
b Incidence rate ratio 
 
Health Service Utilisation Before and After Ventilation 
For the subset of 552 individuals with home ventilator approval and healthcare utilisation data available in the three 
years before and three years after approval, we found an increase in the mean number of respiratory specialist 
outpatient visits per patient from 9 (21.7) to 23 (44.7) visits in three years (P <0.0001). Frequency of PFTs also 
increased whereas frequency of sleep studies decreased (Table 5). We found no difference in frequency of respiratory-
related or all-cause ED visits, hospital or ICU admissions or length of ED visit or hospital length of stay. ICU length 
of stay decreased from a mean of 43.7 to 27.3 days (P=0.04). 
Table 5 Healthcare utilisation before and after initiation of HMV 
N = 552 n (%)a Overall  
priorb 
Overall  
afterc 
P value n (%)d 1 year 
prior 
1 year  
after 
P value 
Respiratory related ED visits   196 (36) 1.7 (1.9) 1.7 (1.8) 0.95 136 (27) 1.4 (1.3) 1.4 (1.0) 0.72 
Length of ED visit , hrs,  - 17.0 (31.8) 16.9 (23.6) 0.97 - 18.9 (32.6) 14.5 (21.4) 0.32 
Respiratory related hospital 
admission  
162 (29) 1.7 (1.4) 1.6 (1.4) 0.62 132 (27) 1.5 (1.2) 1.4 (1.0) 0.70 
Length of hospital stay, days - 30.8 (42.9) 22.9 (36.9) 0.17 - 30.5 (43.4) 24.2 (43.0) 0.38 
Respirology outpatient clinic  443 (80) 8.9 (21.7) 22.7 (44.7) <0.0001 443 (89) 7.4 (20.6) 10.5 (20.1) 0.02 
Hospital respirology consult 47 (9) 7.9 (12.9) 12.3 (28.2) 0.07 47 (9) 7.3 (11.0) 8.7 (13.7) 0.39 
Pulmonary function tests 465 (84) 3.1 (3.0) 4.1 (7) 0.02 448 (90) 2.3 (1.7) 2.8 (5.1) 0.10 
Sleep studies 251 (51) 1.6 (0.9) 1.3 (0.6) <0.0001 229 (46) 1.4 (0.6) 1.1 (0.3) <0.0001 
All cause ED visits  464 (45) 3.9 (4.5) 3.7 (4.9) 0.53 407 (82) 2.4 (2.5) 2.4 (2.5) 0.81 
Length of ED visit, hrs - 25.4 (35.4) 30.9 (44.3) 0.06 - 19.8 (27.6) 19.7 (25.6) 0.93 
All cause hospital admission  406 (74) 2.2 (1.8) 2.2 (2.0) 0.77 347 (70) 1.7 (1.2) 1.7 (1.2) 0.52 
Length of hospital stay, days - 39.0 (81.2) 35.4 (75.7) 0.57 - 37.7 (80.7) 33.0 (81.1) 0.59 
ICU admission 224 (41) 2 (1.72) 2 (1.6) 0.80 175 (35) 1.9 (1.3) 1.6 (1.2) 0.07 
Length of ICU admission, 
days 
- 43.6 (73.5) 27.3 (55.8) 0.04 - 47.0 (77.7) 28.9 (63.4) 0.07 
Ventilated ICU admission 50 (9) 2.4 (1.9) 2.3 (1.6) 0.89 44 (9) 2.3 (1.71) 1.8 (0.9) 0.11 
Length of ventilated 
admission 
- 75.0 (88.8) 34.8 (48.0) 0.02 - 72.1 (88.1) 31.9 (52.5) 0.04 
All values are means (standard deviation) unless otherwise indicated. ALS/MND = 23; Cerebral palsy = 20; Guillain-Barre syndrome < 6; metabolic 
disorders = 7; multiple sclerosis = 15; muscular dystrophy = 52; myasthenia gravis = 59; neuromuscular disorders (non-specific) = 355; neuropathy = 7; 
post-polio syndrome < 6; spina bifida = 6; spinal muscular atrophy < 6. 
a n (%) of individuals that utilized these healthcare services in both the 3 years preceding and the 3 years following approval for publically funded 
HMV. 
b calculated for the 3 years prior to initiation of HMV. 
c calculated for 3 years after initiation of HMV. 
d n (%) of individuals that utilized these healthcare services one year before and one year after initiation of HMV 
 
 
DISCUSSION 
In this retrospective longitudinal population based study of adults with NMD, we found the burden of acute healthcare 
utilisation associated with respiratory complications was moderate with 22% visiting ED, on average 1.6 times every 
3 years and 8% requiring hospital admission, on average 1.4 times every 3 years. Interestingly, of those admitted to 
hospital for respiratory complications, only 9% had an in-patient respiratory specialist consultation. One third of our 
cohort saw respiratory specialists in an outpatient setting on average every nine months and underwent PFT 
monitoring on average every 18 months. In comparison, based on health administration database documentation of 
physician specialty, a neurologist saw only 10% of our cohort of adults with NMD. Approximately 6% of the cohort 
experienced substantial respiratory comorbidity requiring LTOT, CPAP, or HMV. Approval for HMV was 
accompanied by an increase in respiratory specialist outpatient visits and assessment of PFTs in the subsequent three 
years but did not affect the frequency of ED visits or hospitalization. 
 
In this real-world study, for those individuals who received specialist respiratory care, on average frequency of access 
to respiratory specialists, PFT and PSG monitoring reflects current guideline recommendations, although we found 
considerable variability particularly in terms of frequency of clinic visits. The American Thoracic Society [12, 35] and 
Centre for Disease Control and Prevention (CDC) guidelines [9, 13] recommend monitoring and treatment of 
respiratory complications should be performed by respiratory specialists with clinic visits every 3 to 12 months 
depending on disease progress. Similarly, evaluation of PFTs are recommended at baseline and with increasing in 
frequency for those with progressive disease. Reasons for wide variation in visit frequency may be attributed to the 
variable disease progression in NMD, but may also reflect variability in access to specialist respiratory care. 
Comparison with international practice is challenging as data are limited and are not reported at a population level. In 
a US database describing respiratory care over 11 years for 208 males with Duchenne muscular dystrophy, a group 
with progressive disease and generally adherent with therapy with a good response to respiratory interventions, fewer 
than 32% were evaluated by a respiratory specialist in the year 2010-2011 and no more than 50% had PFTs measured 
twice yearly [8]. In a 2011-12 cross sectional European survey, again of Duchenne muscular dystrophy reporting on 
1062 individuals, pulmonary function was not assessed regularly in 71% of non-ambulatory patients [36]. As 
described below, we were unable to isolate Duchenne muscular dystrophy within health administrative databases to 
enable comparison. 
 
Our data demonstrate the considerable burden of NMD on the public healthcare system. All cause public health 
service utilisation for individuals with NMD was substantial with 85% visiting the ED on average more than once a 
year, equivalent to over 1.2 million visits in 12 years, over 50% requiring hospitalization on average twice every three 
years, and 16% requiring ICU admission, twice on average during cohort follow up. After adjusting for multiple 
factors, patients with ALS were the highest users of the ED among our cohort. Reasons for high use of emergent care 
likely include lack of access to specialty care, lack of care integration, lack of respite, and inexperience of general 
practitioners with this disease [37, 38]. From our data, we can conclude that strategies are needed urgently to improve 
community and social supports for all patients with NMD that minimize emergent healthcare utilisation, but 
particularly those with ALS. 
 
Provision of publicly funded respiratory devices and community respiratory therapy was low considering the level of 
respiratory morbidity of the cohort. In Ontario, although all approvals for publicly funded non-invasive and invasive 
ventilators are captured in the Assistive Devices Program database, other respiratory equipment including CPAP and 
bilevel devices may be obtained from non-publicly funded sources or purchased by individuals [39], and therefore our 
data may underestimate the use of respiratory support for NMD. Furthermore, availability of respiratory therapists in 
the community is extremely limited in Ontario [40]. Interestingly, despite a considerable increase in the frequency of 
PFT monitoring and respiratory specialist review after HMV commencement, there was no difference in the need for 
emergent care or hospital admission. Reasons for this might reflect ongoing disease progression or may relate to the 
limited availability of community healthcare workers for ventilator assisted individuals [41]. 
 
A major strength of our study that provides unique data on the respiratory management of NMD is the use of real 
world data from health administrative databases to capture health utilisation on a population based level. Our study 
has limitations. We cannot rule out misclassification, under, or over ascertainment, particularly using physician billing 
codes to identify NMD.  The non-specific neuromuscular category comprised individuals identified with the OHIP 
billing code 349 that likely included individuals with ALS/MND and muscular dystrophy for whom we were unable 
to further delineate diagnosis through an ICD code. Limitations of health administrative database coding prevented 
more disease specific description of healthcare utilisation i.e., Duchenne muscular dystrophy, the most common 
muscular dystrophy, as well as an accurate estimation of disease progression on an individual patient level or within 
disease categories. We were unable to account for other potential confounders of ED presentation or hospital 
admission such as patient mobility status and the primary language spoken as these data are not available in health 
administrative databases. Additionally, health administrative databases do not enable us to assess if all individuals 
with NMD that should have received specialist respiratory care, did receive this care. Lastly, we were unable to assess 
use of airway clearance strategies as mechanical insufflation-exsufflation devices were publicly funded only from 
2014 onwards, prior to this date devices were covered by third party insurers or personal expense.  
 
CONCLUSION 
In this heterogeneous population of adults with NMD, we found approximately one fifth required emergent care for 
respiratory complications and one third received ongoing respiratory specialist care. For those receiving this care, 
frequency of monitoring adhered to guideline recommendations however substantial variation was noted which likely 
reflects variable disease progression but also variable access to specialist care. Emergent healthcare utilisation was 
substantial, emphasizing the burden of NMD on the healthcare system and the urgent need to improve community and 
social supports, particularly for ALS patients. 
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